TransMedics Group (NASDAQ:TMDX) Raised to Buy at Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other equities research analysts have also issued reports on TMDX. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a research note on Tuesday, June 17th. Morgan Stanley upped their target price on TransMedics Group from $115.00 to $123.00 and gave the company an “equal weight” rating in a research note on Friday. Oppenheimer upped their target price on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday, June 17th. Canaccord Genuity Group upped their target price on TransMedics Group from $129.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, July 15th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research note on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, TransMedics Group presently has a consensus rating of “Moderate Buy” and an average target price of $123.00.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $120.55 on Friday. The business’s 50 day simple moving average is $124.51 and its 200-day simple moving average is $95.50. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of 62.46 and a beta of 2.09. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.48 by $0.44. The business had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a return on equity of 28.02% and a net margin of 13.49%. The company’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.35 EPS. As a group, equities analysts forecast that TransMedics Group will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, insider Anil P. Ranganath sold 686 shares of the business’s stock in a transaction on Monday, June 9th. The stock was sold at an average price of $139.80, for a total value of $95,902.80. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. The trade was a 4.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David Weill sold 732 shares of the business’s stock in a transaction on Friday, May 23rd. The shares were sold at an average price of $123.88, for a total value of $90,680.16. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 12,418 shares of company stock worth $1,512,613. Insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Institutional investors and hedge funds have recently made changes to their positions in the company. OneDigital Investment Advisors LLC increased its holdings in shares of TransMedics Group by 52.6% during the 1st quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after buying an additional 2,065 shares during the last quarter. Principal Financial Group Inc. increased its holdings in shares of TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after buying an additional 5,480 shares during the last quarter. Vontobel Holding Ltd. acquired a new stake in shares of TransMedics Group during the 1st quarter worth $291,000. New York State Teachers Retirement System increased its holdings in shares of TransMedics Group by 183.2% during the 1st quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock worth $1,477,000 after buying an additional 14,200 shares during the last quarter. Finally, Sugar Maple Asset Management LLC acquired a new stake in shares of TransMedics Group during the 1st quarter worth $740,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.